Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
X-linked adrenoleukodystrophy (X-ALD) is a fatal neurodegenerative disorder, characterized by progressive cerebral demyelination cerebral childhood adrenoleukodystrophy (CCALD) or spinal cord neurodegeneration (adrenomyeloneuropathy, AMN), adrenal insufficiency and accumulation of very long-chain fatty acids (VLCFA) in tissues. The disease is caused by mutations in the ABCD1 gene, which encodes a peroxisomal transporter that plays a role in the import of VLCFA or VLCFA-CoA into peroxisomes. The Abcd1 knockout mice develop a spinal cord disease that mimics AMN in adult patients, with late onset at 20 months of age. The mechanisms underlying cerebral demyelination or axonal degeneration in spinal cord are unknown. Here, we present evidence by gas chromatography/mass spectrometry that malonaldehyde-lysine, a consequence of lipoxidative damage to proteins, accumulates in the spinal cord of Abcd1 knockout mice as early as 3.5 months of age. At 12 months, Abcd1- mice accumulate additional proteins modified by oxidative damage arising from metal-catalyzed oxidation and glycoxidation/lipoxidation. While we show that VLCFA excess activates enzymatic antioxidant defenses at the protein expression levels, both in neural tissue, in ex vivo organotypic spinal cord slices from Abcd1- mice, and in human ALD fibroblasts, we also demonstrate that the loss of Abcd1 gene function hampers oxidative stress homeostasis. We find that the alpha-tocopherol analog Trolox is able to reverse oxidative lesions in vitro, thus providing therapeutic hope. These results pave the way for the identification of therapeutic targets that could reverse the deregulated response to oxidative stress in X-ALD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, supraphysiological accumulation of C26:0 in astrocytes of ABCD1-deficient mice is followed by production of high reactive oxygen species (15, 16).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [15]
In the citing paper
“Interestingly, Abcd1 knockout mice display oxidative damage to proteins in the spinal cord already at the age of 3 months [39], long before the first neuropathological lesions in the spinal cord at around 16 months of age and clinical signs at 20 months of age [40].”
From X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects (2012) · cites this paper as [39]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“Oxidative stress is a common finding to a growing number of neurodegenerative diseases, although its role as causative factor needs still to be ascertained for most of them (12).”
BackgroundWang, H., & Joseph, J. A. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00107-0 · Cited by 2,346 · cited 2×
“Intracellular ROS levels were estimated using the ROSsensitive H2DCFDA probe as described (27,61).”
MethodHalliwell, B., & Whiteman, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705776 · Cited by 2,238
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623 · cited 1×
“It is tempting to speculate about a scenario comparable with ALS, in which different cell types contribute to different phases of disease progression—motorneurons in early phases of disease onset and microglia in later phases (44).”
ResultInoguchi, T., Li, P., Umeda, F., Yu, H. Y., Kakimoto, M., Imamura, M., Aoki, T., Etoh, T., Hashimoto, T., Naruse, M., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1939 · Cited by 1,577 · cited 1×
“Indeed, a few examples of fatty acids producing ROS via extramitochondrial sources include: (i) the saturated palmitic acid involving activation of NAD(P)H oxidase (47); (ii) arachidonic acid conversion via lipoxygenase (48,49); (iii) the degradation of VLCFA in peroxisomes, which could account for a part of observed…”
BackgroundLocalization of mitochondria in living cells with rhodamine 123.
Johnson, L. V., Walsh, M. L., & Chen, L. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.2.990 · Cited by 1,553
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202 · cited 2×
“The disease is caused by mutations in the ALD gene (official nomenclature ABCD1) that lead to loss of function of the ALD protein (ALDP) (2).”
BackgroundVivekananthan, D. P., Penn, M. S., Sapp, S. K., Hsu, A., & Topol, E. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13637-9 · Cited by 1,083
Mitochondrial Membrane Potential in Living Cells
Chen, L. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.001103 · Cited by 1,037 · cited 1×
“takes benefit of the differential membrane potential to get selectively accumulated in mitochondria (29).”
Background
Cited by
Items 101–200 of 232
Protective function of autophagy during VLCFA-induced cytotoxicity in a neurodegenerative cell model
Doria, M., Nury, T., Delmas, D., Moreau, T., Lizard, G., & Véjux, A. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.04.016 · Cited by 33
Myelin lesions associated with lysosomal and peroxisomal disorders
Faust, P. L., Kaye, E. M., & Powers, J. M. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.127 · Cited by 33
Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy
Deon, M., Marchetti, D. P., Donida, B., Wajner, M., & Vargas, C. R. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0234-2 · Cited by 33
“Furthermore, it has been reported that vitamin E (alfatocopherol) reverses the oxidative damage in fibroblasts from X-ALD patients (Fourcade et al. 2008).”
InfluentialSalsano, E., Tabano, S., Sirchia, S. M., Colapietro, P., Castellotti, B., Gellera, C., Rimoldi, M., Pensato, V., Mariotti, C., Pareyson, D., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-10 · Cited by 32
“It has been suggested that the consequence of the impairment of VLCFA beta-oxidation is an oxidative stress, provoking an axonal damage [1].”
BackgroundSingh, I., Singh, A. K., & Contreras, M. A. (2009) · Journal of Child Neurology · doi:10.1177/0883073809338327 · Cited by 32
Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need
Honey, M. I. J., Jaspers, Y. R. J., Engelen, M., Kemp, S., & Huffnagel, I. C. (2021) · Cells · doi:10.3390/cells10123427 · Cited by 31
“Oxidative damage has been shown to occur before disease onset in a mouse model of ALD [51], and is believed to underlie axonal degeneration, since treatment with antioxidants could counteract this damage [52] as well as reverse locomotor impairment in mice deficient in both ABCD1 and ABCD2 [53].”
BackgroundSelf-citationFourcade, S., Goicoechea, L., Parameswaran, J., Schlüter, A., Launay, N., Ruíz, M., Seyer, A., Colsch, B., Calingasan, N. Y., Ferrer, I., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12869 · Cited by 30
“The first model was the Abcd1- mouse model, which exhibits molecular signs of pathology, including oxidative stress (19) and altered energy homeostasis (23); however, the first clinical signs of AMN (axonopathy and locomotor impairment) appear at 20 months (57,58).”
BackgroundMethodSelf-citationMarchetti, D. P., Donida, B., da Rosa, H. T., Manini, P. R., Moura, D. J., Saffi, J., Deon, M., Mescka, C. P., Coelho, D. D. M., Jardim, L. B., et al. (2015) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2015.03.004 · Cited by 30
“In addition, TRO was able to induce reversion of oxidative lesions in X-ALD fibroblasts (Fourcade et al., 2008).”
BackgroundAntioxidant Capacity and Superoxide Dismutase Activity in Adrenoleukodystrophy
Turk, B. R., Theisen, B. E., Nemeth, C. L., Marx, J. S., Shi, X., Rosen, M. H., Jones, R. O., Moser, A. B., Watkins, P. A., Raymond, G. V., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.5715 · Cited by 30
“Excess C26:0 has been shown togenerate reactiveoxygen species (ROS) anddecreases mitochondrial membrane potential in human cALD fibroblasts.(11) Furthermore, dysfunction of the ubiquitinproteasome“misfoldedproteinclearancesystem”hasbeendescribed as a result of the accumulation of oxidized proteins.”
BackgroundRuíz, M., Bégou, M., Launay, N., Ranea‐Robles, P., Bianchi, P., López‐Erauskin, J., Morató, L., Guilera, C., Petit, B., Vaurs‐Barrière, C., et al. (2017) · Brain Pathology · doi:10.1111/bpa.12571 · Cited by 29
“Cells were then grown as previously described (22).”
BackgroundMethodSelf-citationX-linked adrenoleukodystrophy and primary adrenal insufficiency
Cappa, M., Todisco, T., & Bizzarri, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1309053 · Cited by 28
Stradomska, T. J., Syczewska, M., Jamroz, E., Pleskaczyńska, A., Kruczek, P., Ciara, E., & Tylki‐Szymańska, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238796 · Cited by 28
“In the context of finding elevated lipids peroxidation products in X-ALD patients, the aforementioned conclusion indicates that oxidative stress can be involved in PD pathogenesis [25, 28, 29].”
BackgroundNatural history of a cohort of ABCD 1 variant female carriers
Schirinzi, T., Vasco, G., Aiello, C., Rizzo, C., Sancesario, A., Romano, A., Favetta, M., Petrarca, M., Paone, L., Castelli, E., et al. (2019) · European Journal of Neurology · doi:10.1111/ene.13816 · Cited by 27
“Actually, compelling evidence clearly demonstrates that peroxisomal impairment due to ABCD1 variants causes intertwined, mitochondrial, proteasomal and autophagy dysfunctions, leading to increased oxidative stress first and to neurodegeneration and overt phenotypes later [19,20].”
BackgroundThe pathophysiological role of dihydroceramide desaturase in the nervous system
Tzou, F., Hornemann, T., Yeh, J., & Huang, S. (2023) · Progress in Lipid Research · doi:10.1016/j.plipres.2023.101236 · Cited by 27
Mitochondrial sirtuins – a new therapeutic target for repair and protection in multiple sclerosis
Rice, C. M., Sun, M., Kemp, K. C., Gray, E., Wilkins, A., & Scolding, N. J. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08150.x · Cited by 27
“…& Mahad, 2012; Campbell et al., 2011; Haider et al., 2011; Lassmann & van Horssen, 2011; Pennisi et al., 2011; Stadelmann, 2011) and other white matter disorders, including X-linked adrenoleukodystrophy and Alexander disease (Fourcade et al., 2008; Lopez-Erauskin et al., 2011; Wang et al., 2011).”
BackgroundTherapeutic strategies in adrenoleukodystrophy
Turk, B. R., Moser, A. B., & Fatemi, A. S. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0534-2 · Cited by 26
Redox Imbalance in Neurological Disorders in Adults and Children
Rey, F., Berardo, C., Maghraby, E., Mauri, A., Messa, L., Esposito, L., Casili, G., Ottolenghi, S., Bonaventura, E., Cuzzocrea, S., et al. (2023) · Antioxidants · doi:10.3390/antiox12040965 · Cited by 26
Stearoyl-CoA desaturase-1: a potential therapeutic target for neurological disorders
Loix, M., Vanherle, S., Turri, M., Kemp, S., Fernandes, K. J. L., Hendriks, J. J. A., & Bogie, J. F. J. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00778-w · Cited by 27
Self-citationSOD2 as a potential modifier of X-linked adrenoleukodystrophy clinical phenotypes
Brose, R. D., Avramopoulos, D., & Smith, K. D. (2012) · Journal of Neurology · doi:10.1007/s00415-011-6371-8 · Cited by 27
The Role of Oxidative Stress and Inflammation in X-Link Adrenoleukodystrophy
Yu, J., Chen, T., Guo, X., Zafar, M. I., Li, H., Wang, Z., & Zheng, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.864358 · Cited by 24
“These peroxidation products could exacerbate functional impairment of mitochondria and peroxisomes and further induce oxidative stress and inflammation, leading to cellular damage and death (8, 34, 69, 84, 100, 101).”
BackgroundInfluentialSIRT1 activation alleviates brain microvascular�endothelial dysfunction in peroxisomal disorders
Zhang, Y., Cui, G., Wang, Y., Gong, Y., & Wang, Y. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4250 · Cited by 24
Singh, J., Khan, M., Pujol, A., Baarine, M., & Singh, I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070712 · Cited by 24
“[6,7,9,10,11] leading to astrocytic inflammatory response and loss”
BackgroundSelf-citationCoppa, A., Guha, S., Fourcade, S., Parameswaran, J., Ruiz, M., Moser, A. B., Schlüter, A., Murphy, M. P., Lizcano, J. M., Miranda-Vizuete, A., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.01.177 · Cited by 23
“consequence of fatty acid excess and appears well in advance of the onset of symptoms [47,50] and that the combination of antioxidants Nacetylcysteine, lipoic acid and vitamin E could halt axonal degeneration in the mouse model [49].”
BackgroundSelf-citationLXR antagonists induce ABCD2 expression
Gondcaille, C., Genin, E. C., Lopez, T. E., Dias, A. M. M., Geillon, F., Andreoletti, P., Cherkaoui‐Malki, M., Nury, T., Lizard, G., Weinhofer, I., et al. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.11.003 · Cited by 23
“This increase associated with ABCD1 deficiency is predicted to be caused and amplified by VLCFA accumulation [37].”
Marchetti, D. P., Reinhardt, L. S., Jacques, C. E. D., Guerreiro, G., Mescka, C. P., Deon, M., Coelho, D. D. M., Moura, D. J., Viario, A. G., Poletto, F. S., et al. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0626-1 · Cited by 23
The Value of Mouse Models of Rare Diseases: A Spanish Experience
Murillo‐Cuesta, S., Artuch, R., Asensio, F., de la Villa, P., Dierssen, M., Enríquez, J. A., Fillat, C., Fourcade, S., Ibáñez, B., Montoliu, L., et al. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.583932 · Cited by 23
Self-citationThe effect of bone marrow transplantation on oxidative stress in X-linked adrenoleukodystrophy
Rockenbach, F. J., Deon, M., Marchese, D. P., Manfredini, V., Mescka, C. P., Ribas, G. S., Habekost, C. T., de Castro, C. G., Jardim, L. B., & Vargas, C. R. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.03.019 · Cited by 23
Singh, J., Khan, M., & Singh, I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.01.004 · Cited by 21
Nury, T., Doria, M., Lizard, G., & Véjux, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020641 · Cited by 21
ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy
Volmrich, A. M., Cuénant, L. M., Forghani, I., Hsieh, S. L., & Shapiro, L. T. (2022) · The Application of Clinical Genetics · doi:10.2147/tacg.s359479 · Cited by 21
(2006) · Springer eBooks · doi:10.1007/3-540-29623-9_9160 · Cited by 21
The pathology of X-linked adrenoleukodystrophy: Tissue specific changes as a clue to pathophysiology
Yska, H. A. F., Engelen, M., & Bugiani, M. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03105-0 · Cited by 20
Adrenoleukodystrophy in the era of newborn screening
Eng, L., & Regelmann, M. O. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000515 · Cited by 20
“The VLCFAs are proposed to lead to adrenal insufficiency by direct cytotoxic damage to the cells; oxidative stress leads to apoptosis [34].”
BackgroundPujol, A. (2015) · Endocrine development · doi:10.1159/000439340 · Cited by 20
Self-citationTurk, B. R., Theda, C., Fatemi, A. S., & Moser, A. B. (2019) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2019.11.002 · Cited by 19
Verheijden, S., Beckers, L., Munter, S. D., Veldhoven, P. P. V., & Baes, M. I. (2013) · Biochimie · doi:10.1016/j.biochi.2013.08.009 · Cited by 19
Trompier, D., & Savary, S. (2013) · Colloquium Series on The Genetic Basis of Human Disease · doi:10.4199/c00075ed1v01y201303gbd004 · Cited by 19
RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia
Launay, N., Ruíz, M., Planas‐Serra, L., Verdura, E., Rodríguez‐Palmero, A., Schlüter, A., Goicoechea, L., Guilera, C., Casas, J., Campelo, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162836 · Cited by 18
Self-citationMonternier, P., Singh, J., Parasar, P., Theurey, P., DeWitt, S. H., Jacques, V., Klett, E. L., Kaur, N., Nagaraja, T. N., Moller, D. E., et al. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12510 · Cited by 16
Kartha, R. V., Zhou, J., Basso, L. M., Schröder, H., Orchard, P. J., & Cloyd, J. C. (2015) · CNS Drugs · doi:10.1007/s40263-015-0300-9 · Cited by 16
“Antioxidants including NAC have been shown to confer cellular protection in in vitro and in vivo ALD models [4, 16–19].”
BackgroundZuo, X., & Chen, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02361-0 · Cited by 16
“Oxidative damage is an important early contributor to the pathology of X-ALD and is particularly linked to axonal degeneration [47].”
BackgroundAntioxidant Response in Human X-Linked Adrenoleukodystrophy Fibroblasts
Petrillo, S., D’Amico, J., Nicita, F., Torda, C., Vasco, G., Bertini, E., Cappa, M., & Piemonte, F. (2022) · Antioxidants · doi:10.3390/antiox11112125 · Cited by 15
ABCD1 Transporter Deficiency Results in Altered Cholesterol Homeostasis
Buda, A., Forss-Petter, S., Hua, R., Jaspers, Y., Lassnig, M., Waidhofer-Söllner, P., Kemp, S., Kim, P., Weinhofer, I., & Berger, J. (2023) · Biomolecules · doi:10.3390/biom13091333 · Cited by 14
“Moreover, elevated oxidative stress and lipoxidation resulting in oxidative damage of various cell components have been suggested as a disease mechanism [8].”
BackgroundSelf-citationImbalanced mitochondrial dynamics contributes to the pathogenesis of X-linked adrenoleukodystrophy
Launay, N., Lopez-Erauskin, J., Bianchi, P., Guha, S., Parameswaran, J., Coppa, A., Torreni, L., Schlüter, A., Fourcade, S., Paredes-Fuentes, A. J., et al. (2024) · Brain · doi:10.1093/brain/awae038 · Cited by 14
Self-citationEvolution of adrenoleukodystrophy model systems
Ferrer, R. M., Heine, V. M., Kemp, S., & Engelen, M. (2021) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12357 · Cited by 14
“5 months of age, motor neurons of the spinal cord display oxidative stress as well as oxidative, glycoxidative, and lipoxidative damage to proteins.(42) Excess amounts of VLCFA impair mitochondrial oxidative phosphorylation (OXPHOS) and key enzymes of the tricarboxylic acid (TCA) cycle in the spinal cord of Abcd1 null…”
BackgroundSelf-citationDissecting Peroxisome-Mediated Signaling Pathways: A New and Exciting Research Field
Wang, B., Apanasets, O., Nordgren, M., & Fransen, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1788-0_11 · Cited by 14
Association between APOE4 and biomarkers in cerebral adrenoleukodystrophy
Orchard, P. J., Markowski, T. W., Higgins, L., Raymond, G. V., Nascene, D. R., Miller, W. P., Pierpont, E. I., & Lund, T. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-44140-3 · Cited by 13
Benedetto, R. D., Denti, M. A., Salvati, S., Attorri, L., & Biase, A. D. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.002 · Cited by 13
“This is supported by the evidence of a main role for VLCFA in the generation of ROS in human fibroblasts, identical to the ones found in spinal cords of X-ALD mice, or in X-ALD fibroblasts (Fourcade et al., 2008).”
InfluentialPathophysiology of X-Linked Adrenoleukodystrophy: Updates on Molecular Mechanisms
Parasar, P., Kaur, N., & Singh, J. (2024) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280151 · Cited by 12
“Not only unsaturated but also monounsaturated VLCFA (C26:1) fatty acid also generate ROS in X-ALD fibroblasts and generate free radicals which result in lipid peroxidation whose byproducts cause severe damage to the cells [40].”
BackgroundRevisiting the Pathogenesis of X-Linked Adrenoleukodystrophy
Bougnères, P., & Le Stunff, C. (2025) · Genes · doi:10.3390/genes16050590 · Cited by 11
Hashemi, E., Srivastava, I. N., Aguirre, A., Yoseph, E., Kaushal, E., Awani, A., Ryu, J. K., Akassoglou, K., Talebian, S., Chu, P., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27117 · Cited by 11
Cerebral adrenoleukodystrophy is associated with loss of tolerance to profilin
Orchard, P. J., Nascene, D. R., Gupta, A. O., Taisto, M. E., Higgins, L., Markowski, T. W., & Lund, T. C. (2019) · European Journal of Immunology · doi:10.1002/eji.201848043 · Cited by 11
Ranea‐Robles, P., Galino, J., Espinosa, L., Schlüter, A., Ruíz, M., Calingasan, N. Y., Villarroya, F., Naudí, A., Pamplona, R., Ferrer, I., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12747 · Cited by 10
“organotypic spinal cord slice cultures (OSCSCs) from WT and Abcd1 mice as previously described [22].”
BackgroundMethodSelf-citationAtaxia with giant axonopathy in Acbd5 -deficient mice halted by adeno-associated virus gene therapy
Granadeiro, L., Zarralanga, V. E., Rosa, R., Franquinho, F., Lamas, S., & Brites, P. (2024) · Brain · doi:10.1093/brain/awad407 · Cited by 9
Parameswaran, J., Goicoechea, L., Planas‐Serra, L., Pastor, A., Ruíz, M., Calingasan, N. Y., Guilera, C., Aso, E., Boada, J., Pamplona, R., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02451-2 · Cited by 9
“X-ALD shares physiopathogenic mechanisms with the most common neurodegenerative disorders mentioned above, including oxidative damage, mitochondrial malfunction with bioenergetic failure, lipid droplet accumulation, and chronic inflammation as early intertwined culprits underlying axonal degeneration [31, 34, 35, 50,…”
BackgroundMethodSelf-citationChaudhary, S., Pinky, P., & Parvez, S. (2022) · ACS Omega · doi:10.1021/acsomega.2c00163 · Cited by 9
Mouse Models to Study Peroxisomal Functions and Disorders: Overview, Caveats, and Recommendations
Kocherlakota, S., Swinkels, D., Veldhoven, P. P. V., & Baes, M. I. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3048-8_34 · Cited by 9
Jain, C. K., Maurya, S., & Tripathi, P. K. (2025) · Brain and Development · doi:10.1016/j.braindev.2025.104476 · Cited by 9
Parasar, P., Kaur, N., Poisson, L., & Singh, J. (2023) · Journal of Biotechnology and Biomedicine · doi:10.26502/jbb.2642-91280091 · Cited by 7
“Accumulation of VLCFA associated with oxidative stress, affects OXPHOS [20], and induces mitochondrial dysfunction [4-6].”
BackgroundShim, Y. J., Shin, M. K., Jung, J., Koo, B., & Jang, W. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.996698 · Cited by 7
“X-linked adrenoleukodystrophy (ALD) is a rare ND characterized by fatal progressive cerebral demyelination and/or spinal cord neurodegeneration (Fourcade et al., 2008).”
BackgroundLi, C., Terluk, M. R., & Kartha, R. V. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70044 · Cited by 7
“VLCFA toxicity can increase reactive oxygen species (ROS) production, leading to oxidative stress, impaired mitochondrial function, thereby inducing neuroinflammation in ALD models (Fourcade et al., 2008, 2015; Singh & Pujol, 2010).”
Fatty Acid Metabolism in Peroxisomes and Related Disorders
Morito, K., Ali, H., Kishino, S., & Tanaka, T. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_802 · Cited by 7
Mouse Models of Metachromatic Leukodystrophy and Adrenoleukodystrophy
Aubourg, P. R., Sevin, C., & Cartier, N. (2010) · Neuromethods · doi:10.1007/978-1-60761-898-0_26 · Cited by 6
Sahu, R. K., Yang, Y., & Chung, H.-L. (2026) · iScience · doi:10.1016/j.isci.2026.114724 · Cited by 5
“56 Despite major advances, key aspects of ABCD1 -related disease remain unresolved.”
Isoprostanoid Plasma Levels Are Relevant to Cerebral Adrenoleukodystrophy Disease
Signorini, C., Felice, C. D., Durand, T., Galano, J., Oger, C., Leoncini, S., Hayek, J., Lee, J. C., Lund, T. C., & Orchard, P. J. (2022) · Life · doi:10.3390/life12020146 · Cited by 5
“Discussion Accumulation of VLCFAs is a distinct feature of X-ALD, and oxidative damage has been strongly suggested to be an early driving cause of the X-ALD pathogenesis [5,6,8,48,49].”
BackgroundStradomska, T. J., Drabko, K. A., Moszczyńska, E., & Tylki‐Szymańska, A. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.43787 · Cited by 5
“Other investigations revealed that VLCFA take part in reactive oxygen species formation [3,4,12].”
BackgroundKaur, N., & Singh, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041576 · Cited by 4
Marten, L. M., Lüttgens, M. S., Berečić, B., Tiburcy, M., Brüser, C., Gupta, S., Jakobs, S., Ammer, E., Ohlenbusch, A., Krätzner, R., et al. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.10.289 · Cited by 4
Peroxisomal Pathways, their Role in Neurodegenerative Disorders and Therapeutic Strategies
Risé, P., Paroni, R. C., & Petroni, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00003-x · Cited by 4
Grant, P., & Justus Liebig University Giessen (2011) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-15251 · Cited by 4
C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy
Jaspers, Y. R. J., Dijkstra, I. M. E., Engelen, M., & Kemp, S. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109070 · Cited by 3
Self-citationLeukodystrophies and Lysosomal Storage Disorders
Escolar, M. L., & Aldenhoven, M. (2013) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4614-8357-1_4 · Cited by 3
Development of a rabbit model for adrenoleukodystrophy: A pilot study on gene therapy using rAAV9
Zhou, X., Ma, C.-Y., Zhang, X., Xu, X., Duan, F., Kou, M., Liu, H., Zeng, L., Guo, L., Chen, S., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102469 · Cited by 3
“28 Both endogenous and exogenous VLCFAs can cause tissue damage.”
Singhapakdi, K., Sharma, K., & Maertens, P. M. (2021) · Journal of Pediatric Neurology · doi:10.1055/s-0041-1727143 · Cited by 3
Adrenoleukodystrophy: recent advances in treatment and disease etiology
Drover, V. A. B. (2009) · Clinical Lipidology · doi:10.2217/clp.09.11 · Cited by 3
Estudio de la vulnerabilidad neuronal selectiva en el sistema nervioso central humano
Naudí, A., Jové, M., Ayala, V., Cabré, R., Portero‐Otín, M., Ferrer, I., & Pamplona, R. (2013) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2013.04.005 · Cited by 3
Self-citationSingle Peroxisomal Enzyme and Transporter Deficiencies in Human Diseases and Mouse Models
Kunze, M., & Berger, J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1788-0_8 · Cited by 3
Ferrer, I., & Pujol, A. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2010.00398.x · Cited by 3
“Mouse models are invaluable tools that have allowed gaining insight into pathogenesis, such as identifying oxidative damage as an early contributing factor to the neurodegenerative cascade (3).”
BackgroundSelf-citationMitochondria and Fatty Acid Homeostasis in the Aging Nervous System
Lee, J. R. (2019) · doi:10.11575/prism/36902 · Cited by 3
Cabrera-González, M. I., de Diego‐Otero, Y., Yahyaoui, R., Arriaga, L. R., Aragones, J. L., & Llombart, P. B. (2026) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2026.139886 · Cited by 2
Gragnaniello, V., Gueraldi, D., Puma, A., Commone, A., Cazzorla, C., Loro, C., Porcù, E., Stornaiuolo, M., Miglioranza, P., Salviati, L., et al. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02940-x · Cited by 2
Therapeutics of X-linked adrenoleukodystrophy
Eichler, F., & Aubourg, P. R. (2008) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2009.04.002 · Cited by 2
A novel ABCD1 gene mutation in a Chinese patient with X-linked adrenoleukodystrophy
Cai, Y.-N., Jiang, M., Liang, C., Peng, M.-Z., Cheng, J., Sheng, H., Fan, L.-P., Chen, X.-Q., & Liu, L. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0441 · Cited by 2
Adrenoleucodistrofia : uma forma rara de insuficiência corticosuprarrenal
Raposo, N. F. C. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
X-linked adrenoleukodystrophy; Recent Advances in Classification, Diagnosis and Management
정을식, 강훈철, & 고아라 (2016) · Annals of Child Neurology · doi:10.26815/jkcns.2016.24.3.71 · Cited by 1
Newest therapeutic options for adrenoleukodystrophy
Gołębiowska, M., Gołębiowska, B., & Beń‐Skowronek, I. (2018) · World Scientific News · Cited by 1
Marchetti, D. P., Ribas, G. S., Donida, B., Brito, V. B., Moura, D. J., Coelho, D. D. M., Machado, A. Z., Kessler, R. G., Coitinho, A. S., & Vargas, C. R. (2021) · Clinical & Biomedical Research · doi:10.22491/2357-9730.106453 · Cited by 1
“Additionally, only NAC was able to increase CAT and SOD activity (F[3,8] = 21.”
Backgroundde Lonlay, P., Dubois, S., Valayannopoulos, V., Depondt, E., Ottolenghi, C., & Rabier, D. (2013) · Springer eBooks · doi:10.1007/978-2-8178-0046-2_27 · Cited by 1
Genetic Heterogeneity in Adrenal Insufficiency
Pivonello, R., Simeoli, C., Ferrigno, R., Martino, M. C. D., Menafra, D., de Angelis, C., & Colao, A. A. L. (2021) · Endocrinology · doi:10.1007/978-3-319-89497-3_5 · Cited by 1
Deon, M. (2009) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Pharmacology and Clinical Effects of N-acetylcysteine in Neurodegenerative Disorders
Holmay, M. (2015) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 1
Golbano, A., Pardo, L., Menacho, C., Rierola, M., Claro, E., Wood, L. B., Masgrau, R., & Galea, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.30.510337 · Cited by 1
Marchetti, D. P. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Baarine, M. (2010) · theses.fr (ABES) · doi:10.70675/7ab2bcc8z16d2z420cz92f9zb3fd52371382 · Cited by 1
Preclinical gene therapy using recombinant AAV vectors in mouse models of two human diseases
Günes, Y. Ö. (2022) · theses.fr (ABES) · doi:10.70675/52c9a808z1652z42c4zae82zc812b95f1723 · Cited by 1
Wanders, R. J. A., Ferdinandusse, S., & Waterham, H. R. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1788-0_3
Molecular Genetics of X‐linked Adrenoleukodystrophy
Kemp, S. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0024277
Self-citationTranslational studies in X-linked adrenoleukodystrophy
Engelen, M. (2012) · UvA-DARE (University of Amsterdam)
The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet monkeys
Linde, V. D. R. R., & Johanna, W. (2010)
Guha, S. K. (2015) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Fourcade, S., Lopez-Erauskin, J., Galino, J., Duval, C., Naudi, A., Jove, M., Kemp, S., Villarroya, F., Ferrer, I., Pamplona, R., Portero-Otin, M., & Pujol, A.
- Affiliations
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Amsterdam UMC Location University of Amsterdam (NL)
- Instituto de Salud Carlos III (ES)
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Universitat de Lleida (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Pujol, A.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-04
- Volume
- 17
- Issue
- 12
- Pages
- 1762-1773
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2168163415
- Cited by
- 214
- References
- 67
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 14 · 2023: 10 · 2022: 13 · 2021: 11 · 2020: 9 · 2019: 9 · 2018: 11 · 2017: 11 · 2016: 8 · 2015: 15 · 2014: 14 · 2013: 18 · 2012: 17
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- X-linked adrenoleukodystrophy, ABCD1 gene, oxidative stress, lipid peroxidation, glycoxidation, very long chain fatty acids, adrenomyeloneuropathy, antioxidant defense, Trolox, oxidative protein damage
- MeSH terms
- Superoxide Dismutase 2, Adrenoleukodystrophy, Animals, Catalase, Chromans, Fatty Acids, Fibroblasts, Humans, Lysine, Malondialdehyde, Mice, Inbred C57BL, Motor Neurons, Oxidation-Reduction, Spinal Cord, Superoxide Dismutase, Oxidative Stress, Mice, Membrane Potential, Mitochondrial, Chemokine CCL22, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.